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Introduction
End-stage kidney disease (ESKD) is a complex phenotype 
resulting from underlying kidney disease and interacting 
genetic and environmental factors. Despite rapid improve-
ments in dialysis technology, the mortality rate in dialyzed 
ESKD patients is very high [1, 2]. The identification of 
causative genes predisposing to chronic kidney disease 
and its complications could provide means to better under-
standing the pathogenesis of the disease and result in better 
prevention, diagnosis and treatment [3, 4].
The proteasome is a large multiple subunit enzyme com-
plex that plays a central role in the degradation of intracel-
lular proteins which control transcription rate, cell cycle 
progression and apoptosis [5, 6]. It regulates inflammatory 
processes and plays an important role in pathogenesis of 
human diseases such as cardiovascular diseases, diabetes, 
neurological diseases and cancer [7–10].
The PSMA6 gene is a single copy gene located on 
chromosome 14q13.2 [11]. It codes for a 246 residue pro-
tein called α1 that is structurally important in forming the 
outer α rings of the 20S core proteasome. The α1 protein 
function is also likely to be modulated by posttransla-
tional modifications including phosphorylation, glyco-
sylation and lysine acetylation [12]. The 5′ untranslated 
region of PSMA6 gene contains a single nucleotide poly-
morphism (SNP) −8 C/G (rs1048990) in exon 1. The risk 
conferring G allele enhances the transcription of PSMA6 
[13]. Enhanced PSMA6 activity might exaggerate inflam-
mation through activation of nuclear factor ĸB, a central 
transcription factor regulating expression of the genes 
of cytokines and adhesion molecules [14]. The −8 G/C 
polymorphism was reported to be associated with type 
2 diabetes, myocardial infarction and coronary artery 
disease [13, 15–19].
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In this preliminary case–control study, we investigated 
an association between functional polymorphism −8 C/G 
in PSMA6 gene and end-stage kidney disease.
Patients and methods
Subjects
The study population consisted of 584 unrelated, consecu-
tive adult patients on maintenance dialysis. All patients 
were Caucasians of Polish origin. Chronic kidney disease 
was diagnosed according to KDOQI (Kidney Disease Out-
comes Quality Initiative) definition. ESKD was defined as 
eGFR < 15 ml/min/1.73 m2 associated with clinical signs of 
uremic syndrome requiring dialysis. ESKD resulted mainly 
from primary chronic glomerulonephritis (n = 183), dia-
betic nephropathy (n = 132), interstitial nephritis (n = 71) 
and polycystic kidney disease (n = 45).
Cardiovascular disease was documented in 384 patients, 
as one or the combination of several pathological states: 
congestive heart failure, left ventricular hypertrophy, 
angina pectoris, ischemic heart disease, myocardial infarc-
tion, cerebral stroke or atheromatous lesions. There was a 
substantial overlap between categories. Left ventricular 
hypertrophy (LVH) was diagnosed by electrocardiography 
(ECG) and echocardiography. At the beginning of study, 
426 patients were hypertensive and receiving antihyperten-
sive medications. Hypertension was defined as a systolic 
blood pressure >140 mm Hg and diastolic blood pressure 
>90 mm Hg and/or use of antihypertensive medication.
Healthy control subjects (n = 430) were recruited 
mostly among hospital staff and blood bank donors who 
underwent health examination. All had normal electrocar-
diogram (ECG) and no clinical signs of CVD or renal dis-
ease. Subjects with a positive family history of renal or car-
diovascular disease in first-degree relatives were excluded 
from the study.
An informed consent for participating in genetic studies 
was obtained from all ESKD and control subjects. The pro-
tocol of the study was approved by an institutional ethics 
committee. The investigation conforms to the principles of 
the Declaration of Helsinki.
Determination of PSMA6 genotype
Genomic DNA was extracted from peripheral blood leu-
kocytes prepared by the standard procedure and stored at 
−70 °C before use. The −8 C/G (rs1048990) polymor-
phism in the PSMA6 gene was analyzed by amplifica-
tion of 343 bp DNA fragment by polymerase chain reac-
tion (PCR). Genomic DNA (300 ng) was amplified using 
the following conditions: initial denaturation at 95 °C for 
6 min, followed by 40 cycles of 94 °C for 30 s, annealing 
at 60 °C for 30 s and extension at 72 °C for 1 min. A final 
extension step was at 72 °C for 7 min. 10 μl of the PCR 
product was digested overnight at 37 °C with 5 U of Rsa I 
restriction endonuclease, and resulting fragments were sep-
arated on a 2.5 % agarose gel. The quality of genotyping 
was controlled by using blind DNA duplicates for random 
samples. In addition, 20 samples were randomly selected 
for each genotype and the PCR products were sequenced 
in CEQ8000 Genetic Analysis System (Beckman Coulter, 
England). There was a 100 % concordance between geno-
typing assays.
Statistical analysis
Statistical calculations were performed using SPSS ver-
sion 11.0 for Windows (SPSS, Inc., Chicago, IL, USA). 
For baseline characteristics, the normally distributed con-
tinuous variables are presented as mean ± SD. ANOVA, 
Pearson Χ2 test and Mann–Whitney test were used for 
comparing discrete and continuous variables. The Hardy–
Weinberg equilibrium was assessed using a Χ2 test with 
1 degree of freedom. Genotype distribution and allele fre-
quencies were compared between groups using a Pearson 
Χ2 test of independence with 2 × 2 contingency and z sta-
tistics. For significant allelic and genotyping associations, 
the adjusted odds ratios (OR) with corresponding 95 % 
confidence intervals (CI) were calculated. Power calcu-
lations were performed with the program of Purcell et al. 
(available at http://pngu.mgh.harvard.edu/~purcell/gpc/). 
In the ESKD patient group, the frequency of the PSMA6 
G allele was 0.10. The study had 99.4 % power (α = 0.05) 
to detect an association (OR vs. controls 0.34, 95 % CI 
0.26–0.45). Logistic regression analysis was performed to 
analyze the correlation of genotype and clinical character-
istics, with adjustments for gender and age. Statistical sig-
nificance was set at p < 0.05.
Results
The genotypes of the −8 C/G PSMA6 gene polymorphism 
were determined in 584 ESKD patients and 430 healthy 
individuals. The demographic profile and clinical charac-
teristics of studied ESKD patients and control subjects are 
summarized in Table 1. The ESKD patients presented an 
average age 6 years older than control subjects. They also 
had higher BMI as well as total cholesterol and triglyceride 
levels than controls.
The frequencies of the genotypes and alleles in the con-
trol group were similar to those reported in other studies 
of European populations [16, 20, 21]. Table 2 presents 
the genotypes of the −8 C/G PSMA6 polymorphism in 
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patients and controls. Since the numbers of individuals with 
the GG genotype were small, the carriers of the G allele 
(CG + GG) were combined into one group to increase the 
statistical power. The frequency of the CG + GG genotype 
was lower in ESKD patients than in controls (20 vs. 42 %, 
p = 0.0038). The odds ratio 0.34 (95 % CI 0.26–0.45) 
might suggest an association of the CG + GG genotype 
with decreased risk of end-stage kidney disease.
Left ventricular hypertrophy (LVH) is a strong cardio-
vascular risk marker in end-stage renal disease patients, 
so we also investigated the association between PSMA6 
polymorphism and LVH present in 54 % of our patients 
(Table 3). We observed a strongly significant association 
of the CG + GG genotype with LVH, with over 75 % of 
all CG + GG genotypes found in patients with LVH. 
The logistic regression analysis showed that the effect of 
CG + GG genotype was independent from other common 
causes of LVH—age (OR 1.12, p = 0.643) and hyperten-
sion (OR 1.72, p = 0.422).
Discussion
The ubiquitin–proteasome system and its gene polymor-
phisms are extensively studied, mostly in the cardiovas-
cular field [22]. The functional −8 G/C polymorphism in 
PSMA6 gene was earlier reported to be associated with 
several human diseases—type 2 diabetes, myocardial 
infarction and coronary artery disease [9, 16, 18, 23]. Our 
study was designed to address the potential involvement of 
the PSMA6 gene polymorphism for the first time in chronic 
kidney failure. In our group of patients with ESKD, the 
−8 G/C polymorphism was significantly associated with 
decreased risk of development of end-stage kidney disease. 
The PSMA6 genotype with a G allele might be a protec-
tive factor for the development of end-stage kidney disease. 
Table 1  Demographic and clinical profile of studied subjects
Values are presented as mean ± SD or numbers (%)
ESRD end-stage renal disease
a Where significant
b Triglycerides were determined in 23 % of control subjects
Variables ESRD patients Controls p valuea
N 584 430
Gender (M/F) 331/253 226/204
Age at study (years) 56.2 ± 19 50 ± 17 <0.001
Years on dialysis 4.9 ± 3.3 NA
Diabetes mellitus (%) 132 (23) 0
Hypertension (%) 426 (73) 0
BMI (kg/m2) 27.6 ± 4.5 26.3 ± 3.5 <0.001
Serum creatinine (μmol/l) 789.2 ± 112 ND
Total cholesterol (mmol/l) 5.3 ± 1.81 3.8 ± 1.68 <0.001
HDL cholesterol (mmol/l) 1.2 ± 0.84 ND
Triglycerides (mmol/l) 2.4 ± 1.73 1.16 ± 0.92b <0.001
Table 2  Genotype and allele distribution of PSMA6 SNP in end-stage renal disease patients and controls
Genotype distributions are shown as numbers (%)
ESRD end-stage renal disease, MAF minor allele frequency
a The GG homozygotes were not analyzed separately due to their small number
b OR was adjusted for age, sex and body mass index. The nominal p values were adjusted according to Bonferroni correction
Subjects −8 C/G genotype MAF p value Adjusted OR (95 % CI)b  
for CG + GG genotypes
p value
CC CG + GGa
ESRD (n = 584) 467 (80) 117 (20) 0.10 0.0038 0.34 (0.26–0.45) <0.0001
Controls (n = 430) 249 (58) 181 (42) 0.22 1.0 (reference)
Table 3  Genotype and allele distribution of PSMA6 SNP in ESRD patients with and without LVH
Genotype distributions are shown as numbers (%)
LVH left ventricular hypertrophy, MAF minor allele frequency
a The GG homozygotes were not analyzed separately due to their small number
b OR was adjusted for age, sex and body mass index. The nominal p values were adjusted according to Bonferroni correction
Subjects −8 C/G genotype MAF p value OR (95 % CI)b  
for CG + GG genotypes
p value
CC CG + GGa
LVH (n = 315) 227 (72) 88 (28) 0.14 0.0002 3.21 (2.03–5.06) <0.0001
Without LVH (n = 269) 240 (89) 29 (11) 0.05 1.0 (reference)
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The mechanism of this protective effect needs to be eluci-
dated, with considering also the influence of environmental 
and other coexisting genetic factors. There are two previ-
ous studies, reporting a decreased risk of stroke associated 
with the PSMA6 −8 G/C polymorphism in Caucasian 
populations [20, 21]. In both studies, the authors found a 
protective effect of the PSMA6 rs1048990 SNP on over-
all ischemic stroke, with OR 0.79, p = 0.037 and OR 0.80, 
p = 0.036, respectively. In the Chinese population, the 
PSMA6 rs1048990 CG + GG genotype and G allele were 
protective factors for coronary heart disease [17].
Left ventricular hypertrophy is one of the major car-
diovascular complications of end-stage kidney failure. Left 
ventricular mass increases progressively with duration of 
dialysis treatment, even in normotensive patients [24]. Our 
study shows that the −8 C/G PSMA6 gene polymorphism 
is independently related to LVH in a population of ESKD 
patients. We observed that the presence of CG + GG geno-
types conferred higher risk of the LVH (over threefold) than 
the presence of the CC genotype. There are other studies 
reporting gene variants related to LVH in patients on dialy-
sis [25, 26]. Fedor et al. [27] reported an association of the D 
allele of the angiotensin-converting enzyme polymorphism 
with LVH development after renal transplantation. The 
end-stage kidney disease patients are subjected to pressure 
overload and several hemodynamic and non-hemodynamic 
factors. Thus, in this population of patients, it might be dif-
ficult to explain the mechanism of PSMA6 effect on LVH. 
Also, LVH is caused by lasting effects of several different 
mechanisms on myocardial anatomy and function [28]. The 
functional studies are needed to explore the mechanism of 
PSMA6 effect on LVH. Since the logistic regression analy-
sis we performed showed that the effect of rs1048990 SNP 
on LVH was independent from hypertension, the possibility 
that it is secondary effect, through hypertension, is low.
As most of the association studies, ours has some poten-
tial limitations. A survival and selection bias cannot be 
excluded in this retrospective case–control study. To limit 
this bias, we included consecutive patients and tried to 
adjust for known confounding risk factors, but the comor-
bidities might still represent a confounding factor. The 
strengths of the study are the fairly large size of studied 
groups and that all patients and controls are of the same 
ethnic origin. There was also an adequate statistical power 
of the study for the type I error at 0.05 (99.4 % for ESKD 
vs. controls and 98.1 % for LVH vs. no LVH subgroups). 
All subjects were examined in a standardized manner, with 
well-defined diagnostic criteria, and genotyping was per-
formed blind with respect to case–control status. However, 
the occurrence of kidney diseases, diabetes and comorbidi-
ties such as CVD depends on the interaction among the dif-
ferent risk alleles, environmental factors and the lifestyle. 
The influence of single polymorphisms is rather small, and 
an interactive effect of several factors may lead to an under-
estimation or overestimation of a role of given polymor-
phism in determining the phenotype. These results might 
not therefore apply to populations with different genetic or 
environmental background.
In conclusion, in this study we demonstrated for the first 
time that the PSMA6 gene polymorphism might be a pro-
tective factor for end-stage kidney disease. On the other 
hand, the CG + GG genotypes are independently related to 
LVH in end-stage kidney disease patients.
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